Skip to content

The Association Between Chlorhexidine Bathing and Central Line-Associated Infections in Medical Intensive Care Units

The Association Between Chlorhexidine Bathing Every Other Day and Central Line-Associated Infections in Medical Intensive Care Units: An Observational Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05919966
Enrollment
6930
Registered
2023-06-27
Start date
2023-04-12
Completion date
2023-05-30
Last updated
2023-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Line-associated Bloodstream Infection (CLABSI)

Brief summary

We conducted a retrospective observational cohort study assessing the relationship between regular bathing using 2% CHG wipes every other day and the occurrence of central line-associated infections (CLABSI) in patients within the medical intensive care unit (MICU).

Detailed description

This study defined the post-intervention period as July 1, 2017, to June 30, 2022. During this period, one of the three medical intensive care units (MICUs) in NTUH implemented chlorhexidine gluconate (CHG) bathing as part of their daily care routine (CHG group). This decision was made in response to a higher incidence rate of vancomycin-resistant Enterococcus (VRE) bacteremia observed in that particular MICU during the preceding six months (pre-intervention period: January 1, 2017, to June 30, 2017), compared to the other two MICUs. The remaining two MICUs continued to provide usual care, which involved bathing patients with towels soaked in water and soap on a daily basis.

Interventions

The procedure involved pouring an entire bottle (200ml) of 2% CHG solution (PBF Biotech, Taipei, Taiwan) onto a pre-packed set of eight single-use cotton wipes before each bathing session. A minimum of six wipes were required to thoroughly cover the entire body, including the bilateral upper and lower extremities, front and back of the trunk, perineum, and buttocks.

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* all patients who were admitted to the MICU between January 2017 and June 2022

Exclusion criteria

* patients aged under 18 years old

Design outcomes

Primary

MeasureTime frameDescription
central line-associated bloodstream infectionsWill be surveyed retrospectively through the study period (January 2017 to June 2022)the incidence rate of intensive care unit acquired central line-associated bloodstream infections
multidrug-resistant organisms bacteremiaWill be surveyed retrospectively through the study period (January 2017 to June 2022)the incidence of CLABSIs with blood cultures positive for multidrug-resistant organisms

Secondary

MeasureTime frameDescription
ICU length of stayWill be surveyed retrospectively through the study period (January 2017 to June 2022)the total duration of the patient's ICU stay (days)
hospital length of stayWill be surveyed retrospectively through the study period (January 2017 to June 2022)the total duration of the patient's hospital stay (days)
ICU mortalityWill be surveyed retrospectively through the study period (January 2017 to June 2022)whether the patient has died during their stay in the ICU
hospital mortalityWill be surveyed retrospectively through the study period (January 2017 to June 2022)whether the patient has died during their stay in the hospital

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026